AGNC Investment Corp. · AGNCO · FY2026 Q3 · Calendar Q4 2026
AGNC absorbs Q3 rate shock while defending agency MBS fundamentals
The quarter weakens the near-term earnings picture because rate volatility drove a -12.7% economic return, but the supplied analysis supports a more constructive longer-term case if agency MBS yields, spreads, liquidity and hedging remain favorable. The key test is whether management can convert those fundamentals into returns while controlling leverage, funding and dividend risks.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about AGNCO FY2026 Q3
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
The tone shifted from the prior quarter’s confident outlook to caution after a sharp Q3 rate shock and agency MBS underperformance. AGNC raised $992 million of common stock, increased leverage to 7.9x, reached approximately 97% hedging, and reduced TBA exposure in favor of specified pools.
Guidance delta
No formal guidance was provided. Management discussed deploying capital opportunistically, keeping leverage below 8x, and adapting hedge composition as market conditions improve.
Key takeaways
- Q3 economic return was -12.7%, reflecting sharp Treasury-rate moves and agency MBS underperformance.
- Management highlighted approximately 6.5% agency MBS yields, wide spreads, and an expected 18–20% ROE.
- Liquidity was strengthened by a $992 million common-stock raise; leverage increased modestly to 7.9x and the hedge ratio reached approximately 97%.
- The company reduced net TBA exposure and shifted toward specified pools, while continuing to monitor rates and GSE activity.
Management priorities
- Deploy additional capital opportunistically as macro conditions stabilize.
- Maintain leverage below 8x while preserving strong liquidity.
- Adjust the hedge mix toward swaps as market conditions improve.
- Continue targeted purchases of intermediate-coupon specified pools and monitor GSE activity.
Follow AGNCO with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Neutral | Upgrade | Sep 17, 2023 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 25, 2023 |
| Barclays | Overweight | Overweight | Maintain | Apr 25, 2023 |
| Keefe, Bruyette & Woods | Outperform | Outperform | Maintain | Apr 23, 2023 |
| JP Morgan | Overweight | Overweight | Maintain | Apr 23, 2023 |
| Argus Research | Hold | Buy | Downgrade | Feb 5, 2023 |
| Maxim Group | Buy | Buy | Maintain | Jan 31, 2023 |
| Piper Sandler | Overweight | Overweight | Maintain | Sep 29, 2022 |
| Credit Suisse | Neutral | Neutral | Maintain | May 15, 2022 |
| B of A Securities | Neutral | Buy | Downgrade | Feb 13, 2022 |
| JMP Securities | Market Perform | Market Outperform | Downgrade | Oct 27, 2021 |
| BTIG | Buy | Buy | Maintain | Nov 24, 2020 |
| Deutsche Bank | Buy | Hold | Upgrade | Jul 23, 2020 |
| Wedbush | Outperform | Outperform | Maintain | Apr 8, 2020 |
| Nomura | Buy | Neutral | Upgrade | Mar 15, 2020 |
| Wells Fargo | Perform | Outperform | Downgrade | Apr 11, 2017 |
| Bank of America | Underperform | Neutral | Downgrade | Dec 15, 2016 |
| Compass Point | Neutral | Buy | Downgrade | Dec 7, 2016 |
| Citigroup | Neutral | Neutral | Maintain | Aug 2, 2016 |
| Morgan Stanley | Underweight | Equal Weight | Downgrade | Dec 15, 2015 |
| Wunderlich | Hold | Buy | Downgrade | Oct 27, 2015 |
| Wunderlich Securities | Hold | Buy | Downgrade | Oct 26, 2015 |
| Keefe Bruyette & Woods | Outperform | Outperform | Maintain | Oct 29, 2014 |
| Sandler O'Neill | Hold | Sell | Upgrade | Dec 19, 2013 |
| Goldman Sachs | Sell | Sell | Maintain | Dec 5, 2013 |
| Evercore Partners | Equal Weight | Overweight | Downgrade | Jul 11, 2013 |
| Evercore ISI Group | Equal Weight | Overweight | Downgrade | Jul 10, 2013 |
| Jefferies | Hold | Hold | Maintain | Feb 10, 2013 |
| Stifel Nicolaus | Buy | Buy | Maintain | Nov 7, 2012 |
| Stifel | Buy | Buy | Maintain | Nov 6, 2012 |
| Sterne Agee | Buy | Neutral | Upgrade | Oct 15, 2012 |
| Macquarie | Neutral | Outperform | Downgrade | Aug 14, 2012 |
| Guggenheim | Neutral | Neutral | Maintain | May 2, 2012 |
Track every rating change on AGNCO the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAGNC Investment Corp. functions as a Real Estate Investment Trust (REIT) within the United States, specializing in the residential mortgage market. Its primary investments include residential mortgage-backed securities and collateralized mortgage obligations, all of which benefit from principal and interest payments guaranteed by either a U.S. government-sponsored entity or a direct U.S. government agency. The company primarily finances these investments through secured borrowing arrangements, specifically repurchase agreements. By electing REIT status under the Internal Revenue Code of 1986, AGNC can largely avoid federal corporate income tax, provided it distributes at least 90% of its taxable earnings to its shareholders. The firm was established in 2008 and underwent a name change in September 2016, adopting AGNC Investment Corp. after previously operating as American Capital Agency Corp. Its headquarters are situated in Bethesda, Maryland.
Historical context
All AGNCO earningsReal Estate peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| AHR American Healthcare REIT, Inc. | FY2026 Q3 · Calendar Q4 2026 | -9.0% | +3.3% | AHR raises 2026 outlook as senior-housing NOI growth continues |
| REGCO Regency Centers Corporation | FY2026 Q3 · Calendar Q4 2026 | -32.6% | +2.0% | Regency Centers Q3: Strong Leasing, Higher Guidance, and 2027 Questions |
| REG Regency Centers Corporation | FY2026 Q3 · Calendar Q4 2026 | +94.1% | -1.4% | Regency Centers Raises Outlook as Grocery-Anchored Demand Holds |
| REGCP Regency Centers Corporation | FY2026 Q3 · Calendar Q4 2026 | -32.6% | +0.6% | Regency Centers lifts outlook as occupancy and rent growth strengthen Q3 |
| CPT Camden Property Trust | FY2026 Q3 · Calendar Q4 2026 | -27.2% | -3.1% | Transcript analysis conflicts with CPT event identity |
Latest beats and misses
Who reports nextBeat on EPS
- CRWVFY2026 Q3 · November 10, 20260.0% EPS-0.5% move
- OXYFY2026 Q3 · November 9, 2026+30.8% EPS+2.0% move
- MGREFY2026 Q3 · November 9, 2026+8.1% EPS+0.6% move
- MGRDFY2026 Q3 · November 9, 2026+8.1% EPS+1.4% move
- MGRBFY2026 Q3 · November 9, 2026+8.1% EPS+1.4% move
- AMGFY2026 Q3 · November 9, 2026+8.1% EPS+5.6% move
Missed on EPS
- SEFY2026 Q3 · November 10, 2026-5.1% EPS-1.5% move
- BAPFY2026 Q3 · November 9, 2026-2.6% EPS+3.3% move
- JBSFY2026 Q3 · November 9, 2026-28.6% EPS-5.5% move
- CIBFY2026 Q3 · November 9, 2026-10.1% EPS-4.0% move
- ASTSFY2026 Q3 · November 9, 2026-8.9% EPS-2.3% move
- RKLBFY2026 Q3 · November 9, 2026-79.5% EPS-1.0% move
Get the AGNCO recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-20T16:03:35.565669+00:00
- FN2 earnings calendar · 2026-10-21T01:23:14.182042+00:00
- Polygon adjusted daily market bars · 2026-10-21T06:20:43.334186+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-21. For educational purposes only; not investment advice.